- Arcus Biosciences (RCUS, Financial) to present new data at the 2025 ASCO Annual Meeting.
- First combination data for HIF-2a inhibitor casdatifan and cabozantinib to be showcased.
- Phase 3 trial, PEAK-1, will evaluate the same drug combination.
Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company, is poised to present new findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The oral session will feature data from the Phase 1/1b ARC-20 study cohort, which evaluates the efficacy and safety of the HIF-2a inhibitor casdatifan, in tandem with cabozantinib, for patients with clear cell renal cell carcinoma (ccRCC).
The presentation, scheduled for June 1, 2025, will provide the first combination data for 100mg once-daily casdatifan paired with 60mg once-daily cabozantinib. This regimen targets patients with previously treated ccRCC who have undergone immunotherapy or anti-VEGFR2-TKI therapies.
In addition, Arcus will launch a Phase 3 trial, PEAK-1, to further investigate this combination. The company is also collaborating to assess casdatifan with AstraZeneca’s PD-1/CTLA-4 bispecific antibody, volrustomig, in immuno-oncology-naive ccRCC patients. These developments underscore Arcus's commitment to advancing casdatifan's clinical program.
Furthermore, Arcus Biosciences will conduct a conference call on June 2, 2025, to discuss the ARC-20 data. Investors can join through designated phone numbers or via the live webcast on the company’s website.
Despite promising findings, it is important to note that casdatifan remains an investigational molecule, awaiting regulatory approval. As a global leader in oncology-focused biopharmaceuticals, Arcus continues to innovate in the field, driving forward potential life-extending therapies for cancer patients.
